Guangzhou Psychiatric Hospital

Company snapshot

Guangzhou Psychiatric Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Guangzhou Psychiatric Hospital. Not investment advice.

• What is Guangzhou Psychiatric Hospital?

  Guangzhou Psychiatric Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and U

• Is Guangzhou Psychiatric Hospital publicly traded?

  Guangzhou Psychiatric Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Guangzhou Psychiatric Hospital develop or market?

  We link 1 drug profile(s) where Guangzhou Psychiatric Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/guangzhou-psychiatric-hospital#company-drugs.

• What are the latest developments for Guangzhou Psychiatric Hospital?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Guangzhou Psychiatric Hospital focus on?

  Guangzhou Psychiatric Hospital focuses on Schizophrenia based on our analysis of their pipeline programs and drug development activities.